Itraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients

Clinical Microbiology and Infection

Volumn 12, Issue SUPPL. 7, 2006, Pages 91-96

  Winston, D J ^a  

^a UCLA MEDICAL CENTER   (United States)

Author keywords

Itraconazole; Prophylaxis; Stem cell transplant

Indexed keywords

CYCLODEXTRIN; CYCLOPHOSPHAMIDE; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE;

ALLOGENEIC STEM CELL TRANSPLANTATION; CHEMOPROPHYLAXIS; CHEMOTHERAPY; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION PREVENTION; LIVER TOXICITY; MYCOSIS; NAUSEA; NEPHROTOXICITY; PRACTICE GUIDELINE; PREOPERATIVE CARE; PRIORITY JOURNAL; REVIEW; VOMITING;

ASPERGILLUS;

EID: 33751095096     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2006.01610.x     Document Type: Review

References (23)

1. Wingard JR. Fungal infections after bone marrow transplant. Biol Blood Marrow Transplant 1999; 5: 55-68.
2. Van Burik JH, Leisenring W, Myerson D et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients. Medicine (Baltimore) 1998; 77: 246-254.
3. Schmidt U, Pfaffenbach B, Quabeck K, Donhuijsen K. Fungal infections after bone marrow transplantation-an autopsy study. Mycoses 1991; 34 (suppl 1): 33-35.
4. Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 32: 1319-1324.
5. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-917.
6. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-144.
7. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325: 1274-1277.
8. Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993; 37: 1847-1849.
9. Wolf SN, Fay J, Stevens D et al. Fluconazole vs. low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: A study of the North American Marrow Transplant Group. Bone Marrow Transplant 2000; 25: 853-859.
10. Tollemar J, Ringén O, Andersson S, Sundberg B, Ljungman P, Tyden G. Randomized double-blind study of liposomal amphotericin B (AmBisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993; 12: 577-582.
11. Kelsey SM, Goldman JM, McCann S et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: A randomised, double-blind, placebo-controlled study. Bone Marrow Transplant 1999; 23: 163-168.
12. De Beule KL. Itraconazole: Pharmacology, clinical experience, and future development. Int J Antimicrob Agents Chemother 1996; 6: 175-181.
13. Boogaerts MA, Maertens J, Van Der Geest R et al. Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancy. Antimicrob Agents Chemother 2001; 45: 981-985.
14. Boogaerts M, Winston DJ, Bow EJ et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 2001; 135: 412-422.
15. Winston DJ, Maziarz RT, Chandrasekar PH et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003; 138: 705-713.
16. Glasmacher A, Prentice A, Gorschlüter M et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: Evidence from a meta-analysis of 3,597 patients. J Clin Oncol 2003; 21: 4615-4626.
17. Winston DJ, Emmanouilides C, Bartoni K, Schiller GJ, Paquette R, Territo MC. Elimination of Aspergillus infection in allogeneic stem cell transplant recipients with long-term itraconazole prophylaxis: prevention is better than treatment. Blood 2004; 104: 1581.
18. Marr KA, Crippa F, Leisenring W et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103: 1527-1533.
19. Marr KA, Leisenring W, Crippa F et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004; 103: 1557-1559.
20. Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845-851.
21. Slavin MA, Osborne B, Adams R et al. Efficacy and safety of fluconazole prophylaxis for fungal infection after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995; 171: 1545-1552.
22. Winston DJ, Busuttil RW. Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. Transplantation 2002; 74: 688-695.
23. Herbrecht R, Nivoix Y, Fohrer C, Natarajan-AméS, Letscher-Bru V. Management of systemic fungal infections: Alternatives to itraconazole. J Antimicrob Chemother 2005; 56 (suppl 1): I39-i48.